Par Drugs and Chemicals share news, announcements and annual reports
NSE: PARPharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹109.49.
28 Oct: open ₹109.49, high ₹114.96, low ₹105.01
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 29 Oct 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹141 Cr2,825th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 9.76
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.26
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 8,997
Par Drugs and Chemicals board meetings
102 filed, newest first. Page 1 of 3.
Oct 2026
Aug 2026
13 Aug · Board meeting
8 Aug · Board meeting
Jul 2026
May 2026
14 May · Board meeting
Feb 2026
10 Feb · Board meeting
10 Feb · Board meeting
Jan 2026
Nov 2025
13 Nov · Board meeting
13 Nov · Board meeting
Aug 2025
29 Aug · Board meeting
29 Aug · Board meeting
20 Aug · Board meeting
7 Aug · Board meeting
7 Aug · Board meeting
Jul 2025
Apr 2025
Feb 2025
14 Feb · Board meeting
14 Feb · Board meeting
Jan 2025
11 Jan · Board meeting
8 Jan · Board meeting
Dec 2024
Nov 2024
27 Nov · Board meeting
Oct 2024
22 Oct · Board meeting
22 Oct · Board meeting
Aug 2024
17 Aug · Board meeting
17 Aug · Board meeting
9 Aug · Board meeting
3 Aug · Board meeting
3 Aug · Board meeting
Jul 2024
May 2024
9 May · Board meeting
9 May · Board meeting
Apr 2024
Mar 2024
7 Mar · Board meeting
7 Mar · Board meeting
Feb 2024
28 Feb · Board meeting
16 Feb · Board meeting
16 Feb · Board meeting
8 Feb · Board meeting
Meeting on 16 Feb 2024: “PAR DRUGS AND CHEMICALS LIMITED has informed the Exchange about Board Meeting to be held on 16-Feb-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period”
Oct 2023
28 Oct · Board meeting
28 Oct · Board meeting
Aug 2023
17 Aug · Board meeting